Angion Biomedica Corp. (ANGN)

1.5000 +0.1800 (+13.64%) At close: 04:00PM EDT

Angion Biomedica Corp.

51 Charles Lindbergh Boulevard
Uniondale, NY 11553
United States
415 655 4899
https://www.angion.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 71

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D.	Pres, CEO & Chairman	587.1k	N/A	1972
Dr. John F. Neylan M.D.	Exec. VP, Chief Medical Officer, & Head of Research	468.65k	N/A	1953
Mr. Gregory S. Curhan	Chief Financial Officer	N/A	N/A	1962
Ms. Jennifer J. Rhodes J.D.	Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec.	N/A	N/A	1970
Mr. Daniel Iazzetti	VP of HR	N/A	N/A	N/A
Bruce Rich	Assistant Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Corporate governance

Angion Biomedica Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.